EcoDrugPlus

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSSVLG00005002332
Gene Symbol: PSMD4
1 Cross references
243 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSSVLG00005020636
Gene Symbol: PSMC2
1 Cross references
223 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSSVLG00005025830
Gene Symbol: PSMC4
1 Cross references
197 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSSVLG00005001684
Gene Symbol: PSMC5
1 Cross references
225 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSSVLG00005006842
Gene Symbol: PSMC6
1 Cross references
234 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSSVLG00005012861
Gene Symbol: PSMD1
1 Cross references
210 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSSVLG00005000143
Gene Symbol: PSMD12
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSSVLG00005009509
Gene Symbol: PSMD13
1 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSSVLG00005012351
Gene Symbol: PSMD14
1 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSSVLG00005021483
Gene Symbol: PSMD6
1 Cross references
212 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSSVLG00005002893
Gene Symbol: PSMB11
1 Cross references
227 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSSVLG00005003037
Gene Symbol: PRMT5
1 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).